



Daklinza™ (daclatasvir) – Product discontinuation

- On January 4, 2019, the [FDA announced](#) the discontinuation of Bristol Myers Squibb's [Daklinza \(daclatasvir\)](#) 30 mg and 60 mg tablets.
 - Previously, the FDA announced the discontinuation of Daklinza 90 mg tablets with planned distribution ceasing in December 2018.
 - Bristol Myers Squibb has planned to cease distribution for Daklinza 30 mg and 60 mg tablets in June 2019.
 - All Daklinza tablets are now discontinued.
- Daklinza is indicated for use with [Sovaldi® \(sofosbuvir\)](#), with or without [ribavirin](#), for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection.
 - The sustained virologic response (SVR12) rates are reduced in genotype 3 patients with cirrhosis receiving Daklinza in combination with sofosbuvir for 12 weeks.
- Daklinza carries a boxed warning for risk of hepatitis B virus (HBV) reactivation in patients coinfecting with HCV and HBV.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.